Spots Global Cancer Trial Database for Durvalumab and Oleclumab in Resectable PDAC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Durvalumab and Oleclumab in Resectable PDAC
Official Title: Durvalumab and Oleclumab in Resectable PDAC: A Window of Opportunity Study (DORA Trial)
Study ID: NCT06060405
Conditions
Study Description
Brief Summary: This is a multi-site Canadian, window of opportunity study to evaluate the immune activity of durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma (PDAC) when given prior to surgery.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Contact Details
Name: Malcolm Moore, MD
Affiliation: Princess Margaret Cancer Centre/University Health Network
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
